{'fraction_non_alphanumeric': 0.019925280199252802, 'fraction_numerical': 0.016811955168119553, 'mean_word_length': 5.640495867768595, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Resveratrol benefits the lineage commitment of bone marrow mesenchymal stem cells into osteoblasts via miR‐320c by targeting Runx2

Bone marrow mesenchymal stem cells (BMSCs) are a potential source of osteoblasts and have been widely used in clinical therapies due to their pluripotency. Recent publications have found that resveratrol (RSVL) played a crucial role in the proliferation and differentiation of BMSCs; however, the underlying molecular mechanism of RSVL‐induced BMSCs osteogenic differentiation needs to be fully elucidated. The objective of this study was to explore functions of miRNAs in the RSVL‐treated BMSCs and its effects on the differentiation potentials of BMSCs. The findings demonstrated that RSVL enhanced the osteogenesis and suppressed the adipogenesis of BMSCs in a dose‐dependent manner. Besides, a novel regulatory axis containing miR‐320c, and its target Runx2 was found during the differentiation process of BMSCs under RSVL treatment. Increase of miR‐320c reduced the osteogenic potential of BMSCs, while knockdown of miR‐320c played a positive role in the osteogenesis of BMSCs. In contrast, overexpression of miR‐320c accelerated the adipogenic differentiation, while knockdown of miR‐320c restrained the adipogenic differentiation of BMSCs. The results confirmed that Runx2 might be the direct target of miR‐320c in RSVL‐promoted osteogenic differentiation of BMSCs. This study revealed that RSVL might be used for the treatment of bone loss related diseases and miR‐320c could be regarded as a novel and potential target to regulate the biological functions of BMSCs.